Shares of Quest Diagnostics Inc. DGX slid 1.10% to $178.28 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.23% to ...

Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.

News Summary Seven new systems across Argonne and Los Alamos National Laboratories to be released, accelerating the ...

Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator ...

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

Europe: Labcorp recently took a stake in SYNLAB, a big European lab company. This could be a way to test the waters and see ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

A merger would significantly change the competitive scene. With Quest and Labcorp being major players, their combination ...

Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

Quest Diagnostics ( ($DGX) ) has released its Q3 earnings. Here is a breakdown of the information Quest Diagnostics presented to its investors.

Strong growth, raised guidance, and new partnerships signal continued momentum amid regulatory and cost headwinds.

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.